New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Homex Development Corp. (ADR) (NYSE:HXM), NovaGold Resources Inc. (USA) (NYSEMKT:NG), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Idera Pharmaceuticals Inc (NASDAQ:IDRA)
Homex Development Corp. (ADR) (NYSE:HXM) showed a volume of 2.23 million shares by the end of last trade whereas the average volume of the stock remained 658,767 shares. The stock opened the session at $01.41but then moved to $1.58. At that price, the stock showed a positive performance of 15.33%. Desarrolladora Homex SAB de CV is a Mexico-based homebuilding company. Together with its subsidiaries, the Company is mainly engaged in the promotion, design, development, construction and sale of affordable entry level and middle income residential housing.
Will HXM Continue To Move Higher? Find Out Here
NovaGold Resources Inc. (USA) (NYSEMKT:NG) opened the session at $3.06 and closed the session at $2.90. The stock showed a negative performance of -6.15% in previous trading session. Traded with volume of 2.23 million shares in the prior session and the average volume of the stock remained 1.69 million shares. NovaGold Resources Inc. (NovaGold) is engaged in the exploration and development of mineral properties. The Company has a portfolio of mineral properties located in Alaska, the United States and British Columbia, Canada.
Has NG Found The Bottom And Ready To Gain Momentum? Find Out Here
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) opened the session at $3.45 and closed the session at $3.36. The stock showed a negative performance of -2.33% in previous trading session. Traded with volume of 2.20 million shares in the prior session and the average volume of the stock remained 3.27 million shares. The beta of the stock remained 1.36. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system.
Why Should Investors Buy AVNR After the Recent Fall? Just Go Here and Find Out
Idera Pharmaceuticals Inc (NASDAQ:IDRA) the stock decreased -7.71% and finished the session at $3.71. Traded with volume of 2.16 million shares in the prior session and the average volume of the stock remained 2.83 million shares. The beta of the stock remained 2.03. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates.
Will IDRA Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)